Moh’d khushman

Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer ir.revmed.com/news-releases/…

Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy. 👉Adherence rates were below 75% in all study arms. 👉 No statistically or clinically meaningful difference between the treatment arms. ascopost.com/news/april-202…

#ASCO26 is coming up! With abstracts released I put together a top 10 (ok, top 12) GI abstracts I'm excited for. Some things might fall off (or be added) pending full abstract text, but these are what I'm watching for and might be practice changing or scientifically interesting. @ASCO @Onco_Nexus @OncoAlert @TheGutOncLab

🚨 Mosperafenib enters the BRAF arena! A next-gen paradox breaker for BRAF V600 tumors: ascopubs.org/doi/abs/10.120… @JCO_ASCO ▪️ Phase I (n=80; 60% prior BRAFi; 63 CRC, 13 melanoma) ▪️ MTD not reached → favorable safety ▪️ G3–4 TRAEs: 16.3%; no G5 ▪️ ORR: 24.2% (2 CRs, 14 PRs) ▪️ Sustained target inhibition (pERK ≥90%) ▪️ mPFS: 6.4 mo (CRC) | 3.5 mo (melanoma) Breaking the paradox…one BRAF at a time 🧩 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @GrupoMelanoma @MelanomaReAlli @SocietyMelanoma

ESMO guidelines for localized rectal cancer . #ESMO #oncology #Hematology #medtwitter

Amivantamab in mCRC, hot off the presses 3rd line + chemo-refractory mCRC Terrible disease, great signal OrigAMI-1 (phase 1/2): • RAS/BRAF WT, HER2– • 2–3 prior lines • n=94 Efficacy: • ORR: – 29% (EGFR-naive, left) – 19% (post–EGFR, left) – 22% (right-sided) • PFS: ~3.7–5.7 mo • DoR: ~6–10 mo Signal holds across: • prior EGFR exposure • sidedness Rechallenge signal: • longer interval from prior EGFR → higher ORR (~32%) Toxicity: • Rash / dermatitis (expected) • Infusion reactions common • Low discontinuation Phase 1 always overestimates. But… These response rates are not typical for this setting. If PFS holds in phase 3, this changes practice quickly. And yes, I’m already filling out compassionate use forms on my patient’s behalf. Full Article: ascopubs.org/doi/pdfdirect/… @OncoAlert @TheGutOncLab @Onco_Nexus

One of the most notable studies from #AACR26: Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC. ORR 58% DCR 90% 6-month PFS 84%!! Things are finally moving in pancreatic cancer👇 aacrjournals.org/cancerres/arti…

RevMed absolutely stole the show at AACR with their Pan-RAS and G12D inhibitors. First line panc, second line NSCLC, even in early trials this is extremely compelling data. 2L NSCLC anti G12D (early data): PFS: 11 months ORR: 52% G3 AEs: 13% (Now compare that to 10 months with Osimertinib in 2L NSCLC)… This can’t be FDA approved soon enough. @OncoAlert @TheGutOncLab

In RAS-mutant mPDAC (n=40; efficacy-evaluable n=35), 1L daraxonrasib shows: ✅ ORR 51% ✅ DCR 97% ✅ 6-mo PFS 71% | OS 83% ✅ Deep ctDNA responses (100% VAF reduction; 57% clearance; n=28) ✅ Manageable safety (no G4/5 TRAEs) Encouraging early signal beyond chemotherapy. Phase 3 (RASolute-303) ongoing 🔬 @OncoAlert @Larvol @MedwatchKate #AACR26

In the recent GI publication search, @marshalj23, M.D., discusses new research by @sepideh_gholami, @AnwaarSaeed3,@DemyanLyudmyla, @JoanneXiu, @benweinbergmd, @khushmanmd,@cancerassassin1, Hyo Jung Cho, Minsu Kwon, @JudithVarner2 and others, published in @BMJOncology and @CCR_AACR. Learn more: youtu.be/Ju4ahFKAmtk?si…

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† annalsofoncology.org/article/S0923-…

Ever wondered why BRAF and dMMR go together in colon cancer? Most dMMR CRC is sporadic (~70%), not Lynch. It starts in sessile serrated lesions → early BRAF mutation → CIMP (CpG Island Methylator Phenotype) → MLH1 silencing → dMMR/MSI-H 👉 Why BRAF and not KRAS? BRAF strongly drives CIMP (epigenetic “switch-off”) KRAS does NOT → so MLH1 silencing and dMMR are uncommon 💡 Key point: 👉 BRAF starts the cancer — dMMR defines it So even if BRAF-mutant: ❌ BRAF inhibitors don’t fix mismatch repair 👉 Immunotherapy = 1st line 👉 Treat dMMR first, not BRAF #MVOnco #Oncology #CRC #MSI #GIOncology #MedEd

You can be bullish on daraxonrasib, as I am, and still avoid minimizing side effects like this as “manageable toxicity” We don’t truly understand the visceral experience of taking a medication like our patients do — let’s allow them to be the arbiters of what’s manageable or not

RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we think about KRAS. But—caveat applies ⚠️ This is a press release! PR as a rule is rosier than real data. Still… an OS HR like that gets your attention. Feels like we may be moving from mutation-specific inhibition → broader KRAS control. That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see. Now we wait for the data behind the headline. @TheGutOncLab @OncoAlert @Onco_Nexus ir.revmed.com/news-releases/…

MMR IHC Interpretation – Super Simple Quick Algorithm 🔥 Test the 4 proteins → All present? → pMMR (good) One or more missing? → dMMR (needs attention) Then follow the exact pattern of loss: MLH1 & PMS2 lost (most common) → Check BRAF & MLH1 methylation MSH2 & MSH6 lost → Likely Lynch Only MSH6 or only PMS2 lost → Possible Lynch Weird single losses (MSH2 alone or MLH1 alone) → Not possible, recheck! Key rule: Always read MMR as pairs, not single markers! (MLH1 protects PMS2 • MSH2 protects MSH6) Saves time in daily practice. Save & share! #MVOnco #Oncology #Pathology #MedEd

@AshishManne Congratulations 🎈 Ashish

Excited to share that I will be presenting three posters at the AACR Annual Meeting this year. Grateful to our collaborators and teams who made this possible. Looking forward to discussions, feedback, and new collaborations at AACR. #AACR2026 #PancreaticCancer #AIinMedicine

@HMAbushukair @AACR @thenasheffect @OHLab23 @OncologyScience @StephensonCC Congratulations 🎈 Truly well-deserved

Enjoy!!! #v=onepage&q&f=false" target="_blank" rel="nofollow noopener">books.google.com.pe/books?id=ZVO0D…

Excited, happy and proud to share our @Nature publication on neoadjuvant ICB in pMMR colon cancer; #NICHE! We provide validation of previous clinical results, plus extensive and comprehensive analyses of Overdue tweetorial below❗️ nature.com/articles/s4158…

The day before Xmas...and 2 weeks to #GI26...it's early this year! @ASCO 👇sharing top #GIcancers abstracts I am looking forward to...with special mentions: - HERIZON GEA 01 - ILUSTRO - COMMIT - BREAKWATER (FOLFIRI) Wishing our #oncology X community a Happy Holiday season and look forward to connecting in 2026! 🎉 @OncoAlert